Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Short-term Investments: 2020-2024

Historic Short-term Investments for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $156.6 million.

  • Arcutis Biotherapeutics' Short-term Investments fell 26.45% to $143.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.9 million, marking a year-over-year decrease of 26.45%. This contributed to the annual value of $156.6 million for FY2024, which is 14.63% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Short-term Investments stood at $156.6 million for FY2024, which was down 14.63% from $183.5 million recorded in FY2023.
  • Arcutis Biotherapeutics' 5-year Short-term Investments high stood at $355.9 million for FY2022, and its period low was $156.6 million during FY2024.
  • Over the past 3 years, Arcutis Biotherapeutics' median Short-term Investments value was $183.5 million (recorded in 2023), while the average stood at $232.0 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Short-term Investments spiked by 32.48% in 2021, and later tumbled by 48.46% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Short-term Investments (Yearly) stood at $219.4 million in 2020, then surged by 32.48% to $290.6 million in 2021, then rose by 22.48% to $355.9 million in 2022, then tumbled by 48.46% to $183.5 million in 2023, then declined by 14.63% to $156.6 million in 2024.